SAN DIEGO, May 15, 2019 /PRNewswire/ -- MEI Pharma, Inc.
(NASDAQ: MEIP), a late-stage pharmaceutical company focused on
advancing new therapies for cancer, today announced the publication
of data abstracts related to two of MEI Pharma's clinical
stage drug development programs to be presented at the 2019 ASCO
Annual Meeting to be held May 31 to June 4,
2019 in Chicago. Study
investigators will present updated results from the Phase
1b study evaluating ME-401 in
relapsed/refractory follicular lymphoma and complete results from
the investigator-initiated study of ME-344 in combination with
Avastin® in patients with HER2-negative breast cancer.
The company also announced that an abstract on the PI3Kδ
inhibitor ME-401 was selected for an oral presentation at the 15th
International Conference on Malignant Lymphoma (15-ICML) to be held
June 18-22 in Lugano, Switzerland. The abstract relates to updated
data from the Phase 1b study
evaluating ME-401 in relapsed/refractory follicular lymphoma,
chronic lymphocytic leukemia and small lymphocytic lymphoma, both
as a monotherapy and in combination with rituximab.
"Data updates from our ME-401 program and our ME-344 programs at
ASCO and ICML are the first of a series of notable catalysts for us
heading into the second half of 2019," said Daniel P. Gold,
Ph.D., president and chief executive officer of MEI Pharma. "The
ME-401 program continues to support an emerging potential best in
class clinical profile and distinct therapeutic index, which we
believe is uniquely amenable to combination treatments including
with BTK inhibitors. In addition, mitochondrial inhibitor ME-344
continues to generate investigator support and interest for its
novel MOA and combination potential with Avastin in breast
cancer."
Poster Presentations at ASCO 2019
Title: Results of the PI3Kδ inhibitor ME-401 Alone or
with Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma
(FL)
Date & Time (Poster Display): 6/3/2019,
8:00 -11:00 a.m. CDT
Date & Time (Poster Discussion): 6/3/2019 11:30 a.m.
– 1:00 p.m. CDT
Poster Discussion Session: Hematologic Malignancies—Lymphoma
and Chronic Lymphocytic Leukemia
Abstract: 7512
Author: Andrew David Zelenetz, M.D., Ph.D., Memorial
Sloan Kettering Cancer Center
Title: A Randomized Phase 0 Trial of the Mitochondrial
Inhibitor ME-344 or Placebo Added to the Antiangiogenic (Aa)
Bevacizumab in Early HER2-Negative Breast Cancer (E-HERNEBC)
Date & Time: 6/1/2019, 8:00 -11:00 a.m. CDT
Poster Session: Developmental Therapeutics and Tumor Biology
(Nonimmuno)
Abstract: 3100
Author: Miguel Quintela-Fandino, M.D., Ph.D., Director
of the Clinical Research Program, Centro Nacional De
Investigaciones Oncologicas, Madrid, Spain
Abstracts related to MEI poster presentations at ASCO 2019 may
be found at: https://iplanner.asco.org/am2019/#/
Oral Presentation at 15-ICML 2019
Title: The PI3Kδ Inhibitor ME-401 ± Rituximab in
Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic
Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma
(SLL)
Date & Time: 6/22/2019, 8:30 -10:00 a.m. CEST
Oral Presentation Session: Session 11 -- New Drugs
Combinations
Presenter: Andrew David Zelenetz, M.D., Ph.D., Memorial
Sloan Kettering Cancer Center
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical
company focused on developing potential new therapies for cancer.
Our portfolio of drug candidates contains four clinical-stage
assets, including one candidate in an ongoing global registration
trial and another candidate in a Phase 2 clinical trial which may
support an accelerated approval marketing application with the U.S.
Food and Drug Administration. Each of our pipeline candidates
leverages a different mechanism of action with the objective of
developing therapeutic options that are: (1) differentiated, (2)
address unmet medical needs and (3) deliver improved benefit to
patients either as standalone treatments or in combination with
other therapeutic options. For more information, please
visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-present-new-clinical-results-on-me-401-and-me-344-programs-at-the-2019-american-society-of-clinical-oncology-asco-annual-meeting-300850619.html
SOURCE MEI Pharma, Inc.